← Leaderboards
Joanne Kramer Tobacman
Jesse Brown Va Medical Center
$0
Attributed
$0
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $0 · FY2021–24$1$1$1$0$0
'21
'22
'23
'24
Funding mix
By agency
VA$0 · 1
By mechanism
I01$0 · 1
Top collaborators
No co-investigators on record.
Others in their field
Other Emerging Leaders on “Affect”
- Chanza Baytop · Westat, Inc.$271,217,917
- Leonard Freedman · Leidos Biomedical Research, Inc.$62,378,387
- Jennifer Marie Suga · Kaiser Foundation Research Institute$29,218,159
- Lynn Briscoe · Leidos Biomedical Research, Inc.$27,788,199
- George Robert Painter · University Of Alabama At Birmingham$27,619,145
- Jessica Brooke Langbaum · Banner Health$22,633,312
Research focus
AffectApoptosisArylsulfatase BAnti-Pd1 TherapyBindingBiologicalBreastCancer CellCardiacCd34 GeneCell LineCell PhysiologyCellsCell SurvivalCharacteristicsCheckpoint InhibitionCheckpoint TherapyChondroitinChondroitin Sulfate AChondroitin Sulfate GlycosaminoglycanChondroitin Sulfate ProteoglycanCoculture TechniquesColonDermatan Sulfate
Grant awards (4)
Impact of N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on the Progression of Melanoma$0
I01 · FY2024 · VA · contact PI
Impact of N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on the Progression of Melanoma$0
I01 · FY2023 · VA · contact PI
Impact of N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on the Progression of Melanoma$0
I01 · FY2022 · VA · contact PI
Impact of N-Acetylgalactosamine-4-Sulfatase (Arylsulfatase B) on the Progression of Melanoma$0
I01 · FY2021 · VA · contact PI